Scholarlink

Objective <p>We aimed to investigate the impact of clinical characteristics and therapy on rheumatoid arthritis (RA)-related lung diseases.</p> Methods <p>The retrospective cohort consisted of 1,207 inpatients at baseline. RA-related lung diseases included interstitial lung disease (ILD), bronchiectasis, pleural effusion, and pulmonary arterial hypertension. Kaplan-Meier method was used to measure the cumulative incidence curve. Cox regression was conducted to evaluate the associations between RA-related lung diseases and risk indicators. Logistic regression was employed to examine the impact of drugs.</p> Results <p>The study identified 145 cases of RA-related lung diseases (34.2/1,000 person-years; 95% CI: 28.6–39.7) and 98 RA-ILD cases (22.5/1,000 person-years; 95% CI: 18.0–26.9) over 3.5 years. The cumulative incidence of RA-related lung diseases increased continuously over time, accelerating after 10 years of RA and age 55. RA-related lung diseases was independently associated with older age at RA onset (per 10 years, hazard ratio [HR] = 1.22, 95% confidence interval [CI]: 1.04–1.42), longer RA duration (per 10 years, HR = 1.43, 95% CI: 1.15–1.77), higher Rheumatic Disease Comorbidity Index (HR = 1.22, 95% CI: 1.08–1.39), prior pulmonary infections (HR = 2.26, 95% CI: 1.58–3.24), and systemic lupus erythematosus comorbidity (HR = 2.36, 95% CI: 1.35–4.13). After adjustment, ever-use of methotrexate demonstrated a significant protective association against both RA-related lung diseases (odds ratio [OR] = 0.64, 95% CI: 0.44–0.92) and RA-ILD (OR = 0.54, 95% CI: 0.35–0.83). Similarly, biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) were also found protective (OR = 0.59, 95% CI: 0.35–0.99).</p> Conclusion <p>This study identifies several clinically significant risk factors for RA-related lung diseases, while demonstrating protective effects of methotrexate and b/tsDMARDs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk factors of incident lung diseases and the impact of DMARDs in rheumatoid arthritis patients: a longitudinal study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月3日

查看全文
  • Guangcai Chen,
  • Qing Zhang,
  • Linyu Geng,
  • Yaqi Zhang,
  • Jun Liang,
  • Ziyi Jin,
  • Zhijie Qian,
  • Xinqi Xu,
  • Kexin Zhu,
  • Qing Shu,
  • Xiaojun Tang,
  • Huayong Zhang,
  • Xuebing Feng,
  • Hongwei Chen,
  • Dandan Wang,
  • Lingyun Sun,
  • Wei Shen

摘要

Objective

We aimed to investigate the impact of clinical characteristics and therapy on rheumatoid arthritis (RA)-related lung diseases.

Methods

The retrospective cohort consisted of 1,207 inpatients at baseline. RA-related lung diseases included interstitial lung disease (ILD), bronchiectasis, pleural effusion, and pulmonary arterial hypertension. Kaplan-Meier method was used to measure the cumulative incidence curve. Cox regression was conducted to evaluate the associations between RA-related lung diseases and risk indicators. Logistic regression was employed to examine the impact of drugs.

Results

The study identified 145 cases of RA-related lung diseases (34.2/1,000 person-years; 95% CI: 28.6–39.7) and 98 RA-ILD cases (22.5/1,000 person-years; 95% CI: 18.0–26.9) over 3.5 years. The cumulative incidence of RA-related lung diseases increased continuously over time, accelerating after 10 years of RA and age 55. RA-related lung diseases was independently associated with older age at RA onset (per 10 years, hazard ratio [HR] = 1.22, 95% confidence interval [CI]: 1.04–1.42), longer RA duration (per 10 years, HR = 1.43, 95% CI: 1.15–1.77), higher Rheumatic Disease Comorbidity Index (HR = 1.22, 95% CI: 1.08–1.39), prior pulmonary infections (HR = 2.26, 95% CI: 1.58–3.24), and systemic lupus erythematosus comorbidity (HR = 2.36, 95% CI: 1.35–4.13). After adjustment, ever-use of methotrexate demonstrated a significant protective association against both RA-related lung diseases (odds ratio [OR] = 0.64, 95% CI: 0.44–0.92) and RA-ILD (OR = 0.54, 95% CI: 0.35–0.83). Similarly, biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) were also found protective (OR = 0.59, 95% CI: 0.35–0.99).

Conclusion

This study identifies several clinically significant risk factors for RA-related lung diseases, while demonstrating protective effects of methotrexate and b/tsDMARDs.